Deletion of RAGE fails to prevent hepatosteatosis in obese mice due to impairment of other AGEs receptors and detoxifying systems

K. Wouters, A.S. Cento, K.H. Gaens, M. Teunissen, J.L.J.M. Scheijen, F. Barutta, F. Chiazza, D. Collotta, M. Aragno, G. Gruden, M. Collino, C.G. Schalkwijk, R. Mastrocola*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Advanced glycation endproducts (AGEs) are involved in several diseases, including NAFLD and NASH. RAGE is the main receptor mediating the pro-inflammatory signalling induced by AGEs. Therefore, targeting of RAGE has been proposed for prevention of chronic inflammatory diseases. However, the role of RAGE in the development of NAFLD and NASH remains poorly understood. We thus aimed to analyse the effect of obesity on AGEs accumulation, AGE-receptors and AGE-detoxification, and whether the absence of RAGE might improve hepatosteatosis and inflammation, by comparing the liver of lean control, obese (LeptrDb-/-) and obese RAGE-deficient (RAGE-/- LeptrDb-/-) mice. Obesity induced AGEs accumulation and RAGE expression with hepatosteatosis and inflammation in LeptrDb-/-, compared to lean controls. Despite the genetic deletion of RAGE in the LeptrDb-/- mice, high levels of intrahepatic AGEs were maintained accompanied by decreased expression of the protective AGE-receptor-1, impaired AGE-detoxifying system glyoxalase-1, and increased expression of the alternative AGE-receptor galectin-3. We also found sustained hepatosteatosis and inflammation as determined by persistent activation of the lipogenic SREBP1c and proinflammatory NLRP3 signalling pathways. Thus, RAGE targeting is not effective in the prevention of NAFLD in conditions of obesity, likely due to the direct liver specific crosstalk of RAGE with other AGE-receptors and AGE-detoxifying systems.
Original languageEnglish
Article number17373
Number of pages13
JournalScientific Reports
Volume11
Issue number1
DOIs
Publication statusPublished - 30 Aug 2021

Keywords

  • GLYCATION END-PRODUCTS
  • INSULIN-RESISTANCE
  • DIABETIC COMPLICATIONS
  • INFLAMMATORY RESPONSE
  • OXIDATIVE STRESS
  • LIVER STEATOSIS
  • RENAL-FUNCTION
  • MOUSE MODELS
  • EXPRESSION
  • GALECTIN-3

Cite this